adss-1 Antibody

Molecular and Functional Overview of ADSS1

ADSS1 (Gene ID: 122622) encodes adenylosuccinate synthetase isozyme 1, a key enzyme in the purine nucleotide cycle (PNC). It catalyzes the conversion of inosine monophosphate (IMP) to adenylosuccinate, a precursor for AMP synthesis. Mutations in ADSS1 cause a rare autosomal recessive myopathy characterized by progressive muscle weakness, respiratory failure, and cardiac involvement .

Research Applications and Findings

ADSS1 antibodies are instrumental in diagnosing and studying ADSS1 myopathy, as well as elucidating purine metabolism pathways:

• ADSS1 Myopathy Research:

  • Pathogenesis: Antibodies detect ADSSL1 protein loss in muscle biopsies, correlating with lipid accumulation and vacuolar myopathy .

  • Animal Models: ADSS1 knockdown in zebrafish and murine myoblasts replicates myopathy phenotypes, enabling drug screening .

  • Biomarker Discovery: Serum ADSS1 levels may serve as diagnostic markers, though validation is ongoing .

• Purine Metabolism Studies:

  • Biochemical Assays: Antibodies validate ADSS1’s role in coupling GTP hydrolysis to IMP-aspartate ligase activity .

  • Therapeutic Targets: Inhibitors of compensatory pathways (e.g., AMPD1) are explored using ADSS1-deficient models .

• Vaccine Development:

  • Bacterial Targets: PurA (homologous to ADSS1) in Streptococcus equi spp. zooepidemicus (SEZ) is immunogenic, with antibodies reducing bacterial colonization .

Challenges and Future Directions

• Specificity: Cross-reactivity with non-muscle ADSS isoforms remains a concern in diagnostic applications .

• Therapeutic Development: Antibodies may aid in validating gene therapy or small-molecule candidates targeting ADSS1 deficiency .

• Standardization: Consensus on optimal dilutions and protocols is needed to harmonize research findings .